Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epoxy-oxylipins direct monocyte fate in inflammatory resolution in humans.

Nature communications·2026
Same author

Anti-growth and pro-apoptotic effects of dasatinib on human oral cancer cells through multi-targeted mechanisms.

Journal of cellular and molecular medicine·2021
Same author

Genome to phenome tools: In vivo and in vitro transfection of Crassostrea virginica hemocytes.

Fish & shellfish immunology·2020
Same author

Vascular Lipidomic Profiling of Potential Endogenous Fatty Acid PPAR Ligands Reveals the Coronary Artery as Major Producer of CYP450-Derived Epoxy Fatty Acids.

Cells·2020
Same author

Anti‑survival and pro‑apoptotic effects of meridianin C derivatives on MV4‑11 human acute myeloid leukemia cells.

International journal of oncology·2019
Same author

Lipid mediators in immune regulation and resolution.

British journal of pharmacology·2019

Related Experiment Video

Updated: Jun 27, 2026

Establishing a Physiologic Human Vascularized Micro-Tumor Model for Cancer Research
07:26

Establishing a Physiologic Human Vascularized Micro-Tumor Model for Cancer Research

Published on: September 15, 2023

Tumour vascularisation: a druggable target.

David Bishop-Bailey1

  • 1Translational Medicine and Therapeutics, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London, Charterhouse Square, London EC1M 6BQ, United Kingdom. d.bishop-bailey@qmul.ac.uk

Current Opinion in Pharmacology
|December 6, 2008
PubMed
Summary
This summary is machine-generated.

Tumour growth relies on new blood vessel formation, known as angiogenesis. Targeting vascular endothelial growth factors (VEGFs) offers a strategy to inhibit tumour vascularization and limit cancer spread.

More Related Videos

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice
08:52

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Published on: January 19, 2018

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Experiment Videos

Last Updated: Jun 27, 2026

Establishing a Physiologic Human Vascularized Micro-Tumor Model for Cancer Research
07:26

Establishing a Physiologic Human Vascularized Micro-Tumor Model for Cancer Research

Published on: September 15, 2023

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice
08:52

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Published on: January 19, 2018

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Area of Science:

  • Oncology
  • Vascular Biology
  • Cancer Research

Background:

  • Tumour growth, invasion, and metastasis are critically dependent on the development of a local vasculature.
  • Significant advancements have been made in understanding angiogenesis, the process of new blood vessel formation.
  • Hypoxia-induced production of vascular endothelial growth factors (VEGFs) is a key signaling process in tumour vasculature development.

Purpose of the Study:

  • To investigate the role of angiogenesis in tumour development.
  • To explore the potential of anti-VEGF therapy in limiting tumour growth and metastasis.
  • To test the hypothesis that controlling tumour vasculature development can inhibit cancer progression.

Main Methods:

  • Identification of pro-angiogenic and anti-angiogenic mediators.
  • Focus on hypoxia-induced stimulation of vascular endothelial cell growth factors (VEGFs).
  • Utilizing anti-VEGF agents as therapeutic tools.

Main Results:

  • Vascular endothelial growth factors (VEGFs) play a crucial role in tumour angiogenesis.
  • Anti-VEGF therapy targets the development of tumour vasculature.
  • Controlling tumour vasculature is a viable strategy for limiting tumour growth and spread.

Conclusions:

  • Targeting angiogenesis, specifically VEGF signaling, is a promising therapeutic approach for cancer.
  • Anti-VEGF therapies represent a new paradigm for cancer treatment by inhibiting tumour vascularization.
  • Controlling the tumour vasculature is key to limiting tumour growth, spreading, and metastasis.